MA
ERNA icon

Montag & Associates’s Eterna Therapeutics ERNA Stock Holding History

Montag & Associates’s Portfolio ERNA Stock Details ERNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Hold
0
– -$2 – 965
2026
Q1 		– Hold
0
– – – 940
2025
Q4 		– Hold
0
– – – 950
2025
Q3 		– Hold
0
– – – 1119
2025
Q2 		– Hold
0
– – – 948
2025
Q1 		– Sell
-1
Closed -$123 – 992
2024
Q4 		$63 Hold
1
– – ﹤0.01% 992
2024
Q3 		$223 Hold
1
– – ﹤0.01% 1018
2024
Q2 		$388 Buy
+1
New +$752 ﹤0.01% 969
2024
Q1 		– Hold
0
– – – 963
2023
Q4 		– Hold
0
– – – 904
2023
Q3 		– Hold
0
– – – 897
2023
Q2 		– Hold
0
– – – 918
2023
Q1 		– Hold
0
– – – 918
2022
Q4 		– Hold
0
– – – 938
2022
Q3 		– Hold
0
– – – 873
2022
Q2 		– Hold
0
– – – 789
2022
Q1 		– Hold
0
– – – 771
2021
Q4 		– Hold
0
– – – 759
2021
Q3 		– Hold
0
– – – 707
2021
Q2 		– Hold
0
– – – 636

Other funds holding ERNA

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
DIG
Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tradewinds Capital Management Bellingham, Washington $563M AUM 41.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return

Montag & Associates's ERNA Position: Q2 2026 in Review

Montag & Associates held its Eterna Therapeutics (ERNA) position steady in Q2 2026 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #965.

Montag & Associates first reported a position in ERNA in Q2 2024 and has held it in 3 quarters since. The position peaked at $388 in Q2 2024. 9 funds tracked by Wall St. Rank hold ERNA as of Q2 2026.

  • Montag & Associates held 0 shares of Eterna Therapeutics worth $0 as of Q2 2026.
  • Montag & Associates left its Eterna Therapeutics share count unchanged in Q2 2026.
  • Eterna Therapeutics made up ﹤0.01% of Montag & Associates's portfolio in Q2 2026, its #965 holding.
  • Montag & Associates first reported a position in Eterna Therapeutics in Q2 2024 and has held it in 3 quarters since.
  • Montag & Associates's Eterna Therapeutics position peaked at $388 in Q2 2024.
  • 9 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q2 2026.

Based on Montag & Associates's 13F filing for Q2 2026, filed 5 Aug 2026.